# DNA — Ginkgo Bioworks · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** DNA  
**Sources:** 20  
**Published:** 2026-10-25  
**Canonical:** https://app.k3vl4r.com/research/deep-research-dna-ginkgo-bioworks-catalysts-narrative-risks-9045

---

# Ginkgo Bioworks (NYSE: DNA) — As of October 25, 2026

Below is a point-in-time research summary. It is informational only, not investment advice.

## Company snapshot (Oct 23, 2026)
- NYSE-listed biotech developing a cell-engineering platform [[16]](https://www.marketbeat.com/stocks/NYSE/DNA/), [[18]](https://markets.financialcontent.com/wss/quote/ny:dna).
- Price ~$9.99, market cap ~$672.7M, ~67.34M shares outstanding, beta 1.79 [[20]](https://stockanalysis.com/stocks/dna/).
- 52-week range $5.37–$18.22 [[20]](https://stockanalysis.com/stocks/dna/). Over the trailing 12 months DNA fell roughly 26% while the S&P 500 rose ~12% [[18]](https://markets.financialcontent.com/wss/quote/ny:dna).
- Fundamentals are weak relative to peers: trailing revenue ~$132.4M (−37%) and net loss ~$290.8M, EPS −$4.96 [[20]](https://stockanalysis.com/stocks/dna/). For context, 2025 revenue was $170.2M, down ~25% [[20]](https://stockanalysis.com/stocks/dna/). (Note [[1]](https://www.timothysykes.com/news/ginkgobioworksholdingsinc-dna-news-2026_10_11/) cites "~$170M revenue," which appears to reflect the 2025 annual figure rather than the trailing-twelve-month number.)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-dna-ginkgo-bioworks-catalysts-narrative-risks-9045 (free to sign up)._
